Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb;100 Suppl 2(Suppl 2):S1-44.
doi: 10.1097/TP.0000000000001055.

Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement

Affiliations

Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement

Stephen T Bartlett et al. Transplantation. 2016 Feb.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest declarations for meeting participants: (1) Choudhary P: Medtronic Ltd. (clinical studies); Abbot Ltd. (2) Hering B: Novartis; Sanofi. (3) Korsgren O: TikoMed, Inc. (production of LMWDS); I Reg Medical (Production of Treg); I Cell Science (production of MSL). (4) O'Connell P: Novartis (local advisory); Jansen Silag (Local advisory); Astellas (Invited lecturer at educational symposia). (5) Odorico J: Regenerative Medical Solutions, Inc. (co-founder, chair, scientific advisory board). (6) Stabler C: University of South Florida (Webinar presenter); Converge Biotech (license technology, scientific advisor). (7) Weir G: Novo Nordisk (speaker); Novartis (speaker); Merck (speaker); Pfizer (consult).

Figures

FIGURE 1
FIGURE 1
Expected changes in β cell replacement over time. before the conclusion of the conference, a web based survey was completed by the participants seeking their individual opinion as to what portion of the β-cell replacement market would be captured by the existing and potential therapies discussed at the meeting. For each of the time horizons of 5, 10, and 20 years, respondents allocated predicted market share between 9 potential therapeutic options. The graph shows the average market share awarded to specific therapies at 5, 10, and 20 years.

References

    1. Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967; 61: 827– 837. - PubMed
    1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993; 329: 977– 986. - PubMed
    1. Writing Group for the DCCT/EDIC Research Group; Orchard TJ, Nathan DM, et al. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality. JAMA. 2015; 313: 45– 53. - PMC - PubMed
    1. Livingstone SJ, Levin D, Looker H, et al. Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA. 2015; 313: 37– 44. - PMC - PubMed
    1. Katz M, Laffel L. Mortality in type 1 diabetes in the current era: two steps forward, one step backward. JAMA. 2015; 313: 35– 36. - PubMed

Publication types

MeSH terms

Substances